首页> 外文OA文献 >A phase I study of multi-HLA-binding peptides derived from heat shock protein 70/glypican-3 and a novel combination adjuvant of hLAG-3Ig and Poly-ICLC for patients with metastatic gastrointestinal cancers: YNP01 trial

【2h】

A phase I study of multi-HLA-binding peptides derived from heat shock protein 70/glypican-3 and a novel combination adjuvant of hLAG-3Ig and Poly-ICLC for patients with metastatic gastrointestinal cancers: YNP01 trial

机译：阶段I研究来自热休克蛋白70 /甘锡-3的多HLA结合肽，以及用于转移胃肠癌患者的HLAG-3IG和Poly-ICLC的新型组合佐剂：YNP01试验

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Masao Nakajima; Shoichi Hazama; Koji Tamada; Keiko Udaka; Yasunobu Kouki; Toshinari Uematsu; Hideki Arima; Akira Saito; Shun Doi; Hiroto Matsui; Yoshitaro Shindo; Satoshi Matsukuma; Shinsuke Kanekiyo; Yukio Tokumitsu; Shinobu Tomochika; Michihisa Iida; Shin Yoshida; Yuki Nakagami; Nobuaki Suzuki; Shigeru Takeda; Shigeru Yamamoto; Shigefumi Yoshino; Tomio Ueno; Hiroaki Nagano;
展开▼
作者单位

展开▼
年度 2020
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. A phase I study of multi-HLA-binding peptides derived from heat shock protein 70/glypican-3 and a novel combination adjuvant of hLAG-3Ig and Poly-ICLC for patients with metastatic gastrointestinal cancers: YNP01 trial [J] . Nakajima Masao, Hazama Shoichi, Tamada Koji, Cancer immunology, immunotherapy : . 2020,第8期

机译：衍生自热休克蛋白70 /甘锡-3的多HLA结合肽的I阶段研究，以及用于转移胃肠癌患者的HLAG-3IG和Poly-ICLC的新型组合佐剂：YNP01试验
2. Heat Shock Protein 70 (Hsp70) Peptide Activated Natural Killer (NK) Cells for the Treatment of Patients with Non-Small Cell Lung Cancer (NSCLC) after Radiochemotherapy (RCTx) – From Preclinical Studies to a Clinical Phase II Trial [J] . Hanno M. Specht, Norbert Ahrens, Christiane Blankenstein, Frontiers in Immunology . 2015,第12期

机译：热休克蛋白70（Hsp70）肽激活的自然杀伤（NK）细胞用于放射化学治疗（RCTx）后的非小细胞肺癌（NSCLC）患者的治疗-从临床前研究到临床II期试验
3. Heat Shock Protein 70 (Hsp70) Peptide Activated Natural Killer (NK) Cells for the Treatment of Patients with Non-Small Cell Lung Cancer (NSCLC) after Radiochemotherapy (RCTx) – From Preclinical Studies to a Clinical Phase II Trial [J] . Hanno M. Specht, Norbert Ahrens, Christiane Blankenstein, Frontiers in Immunology . 2015,第4期

机译：热休克蛋白70（Hsp70）肽激活的自然杀伤（NK）细胞用于放射化学治疗（RCTx）后的非小细胞肺癌（NSCLC）患者的治疗-从临床前研究到临床II期试验
4. Phase I/II clinical trials on the effect of weekly paclitaxel (wPTX) and wPTX containing combination regimens for advanced and metastatic gastric cancer -ECRIN group studies [C] . Sakamoto J, Kodera Y, Kobayashi M, International Gastric Cancer Congress . 2009

机译：I / II期临床试验关于每周紫杉醇（WPTX）和WPTX含有晚期和转移性胃癌组合方案的临床试验 - 分泌组研究
5. A phase I study of multi-HLA-binding peptides derived from heat shock protein 70/glypican-3 and a novel combination adjuvant of hLAG-3Ig and Poly-ICLC for patients with metastatic gastrointestinal cancers: YNP01 trial [O] . Masao Nakajima, Shoichi Hazama, Koji Tamada, -1

机译：INP研究：热休克蛋白70 / glypican-3衍生的多种HLA结合肽以及hLAG-3Ig和Poly-ICLC的新型联合佐剂用于转移性胃肠道癌患者：YNP01试验
6. Review article: Heat shock protein 70 (Hsp70) peptide activated Natural Killer (NK) cells for the treatment of patients with non-small cell lung cancer (NSCLC) after radiochemotherapy (RCTx) – from preclinical studies to a clinical phase II trial [O] . Hanno M Specht, Norbert eAhrens, Christiane eBlankenstein, 2015

机译：综述文章：热休克蛋白70（Hsp70）肽激活自然杀伤（NK）细胞用于治疗放疗后非小细胞肺癌（NsCLC）患者（RCTx） - 从临床前研究到临床II期试验

A phase I study of multi-HLA-binding peptides derived from heat shock protein 70/glypican-3 and a novel combination adjuvant of hLAG-3Ig and Poly-ICLC for patients with metastatic gastrointestinal cancers: YNP01 trial

著录项

引文网络

相似文献

相关主题

期刊订阅